Remission in rheumatoid arthritis:Benefit over low disease activity in patient-reported outcomes and costs

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Radner, Helga ^a   Smolen, Josef S ^a   Aletaha, Daniel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; EURO QOL 5D; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE; OUTCOME ASSESSMENT; PRODUCTIVITY; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; SHORT FORM 6 DIMENSIONS; SIMPLIFIED DISEASE ACTIVITY INDEX; WORK; ARTHRITIS, RHEUMATOID; ECONOMICS; MIDDLE AGED; QUESTIONNAIRE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84897479986     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4491     Document Type: Article

References (44)

1. Kobelt G, Jonsson B. The burden of rheumatoid arthritis and access to treatment:outcome and cost-utility of treatments. Eur J Health Econ 2008, 8:95-106. 10.1007/s10198-007-0091-0, 18157559.
2. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis:an international long-term view. Semin Arthritis Rheum 2000, 29:305-320. 10.1016/S0049-0172(00)80017-7, 10805355.
3. Fries JF. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis 1999, 58:I86-I89. 10.1136/ard.58.2008.i86, 1766585, 10577980.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
5. Kvamme MK, Lie E, Kvien TK, Kristiansen IS. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases:data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford) 2012, 51:1618-1627. 10.1093/rheumatology/kes074, 22539479.
6. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009, 60:1242-1249. 10.1002/art.24433, 19404938.
7. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate:the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009, 68:823-827. 10.1136/ard.2008.090019, 18593759.
8. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis:identifying reversible and irreversible components. Arthritis Rheum 2006, 54:2784-2792. 10.1002/art.22052, 16947781.
9. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004, 31:849-855.
10. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, Kalden JR, Schiff M, Bala M, Baker D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006, 54:716-722. 10.1002/art.21661, 16508932.
11. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, et al. EULAR recommendations for the management of early arthritis:report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:34-45. 1798412, 16396980.
12. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140.
13. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment:health burden and costs. Eur J Health Econ 2008, 8:S49-S60. 10.1007/s10198-007-0088-8, 18157732.
14. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewe R, Smolen JS, Aletaha D. Economic aspects of treatment options in rheumatoid arthritis:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:995-1003. 10.1136/ard.2009.126714, 20447950.
15. Stamm TA, Aletaha D, Pflugbeil S, Kapral T, Montag K, Machold KP, Smolen JS. The use of databases for quality assessment in rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:82-85.
16. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:validation of a clinical activity score. Arthritis Res Ther 2005, 7:R796-R806. 10.1186/ar1740, 1175030, 15987481.
17. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003, 42:244-257. 10.1093/rheumatology/keg072, 12595618.
18. Prevoo ML, Hof M, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts:development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
19. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis:defining criteria for disease activity states. Arthritis Rheum 2005, 52:2625-2636. 10.1002/art.21235, 16142705.
20. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006, 65:1175-1183. 10.1136/ard.2005.046367, 1798296, 16540552.
21. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36):II, psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263. 10.1097/00005650-199303000-00006, 8450681.
22. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36):I. conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
23. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998, 51:1115-1128. 10.1016/S0895-4356(98)00103-6, 9817129.
24. The EuroQol Group EuroQoL:a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
25. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire:general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R177. 10.1186/ar3141, 2991008, 20860837.
26. Li LC, Maetzel A, Davis AM, Lineker SC, Bombardier C, Coyte PC. Primary therapist model for patients referred for rheumatoid arthritis rehabilitation:a cost-effectiveness analysis. Arthritis Rheum 2006, 55:402-410. 10.1002/art.21989, 16739183.
27. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis:a systematic literature review. Pharmacoeconomics 2005, 23:243-257. 10.2165/00019053-200523030-00005, 15836006.
28. Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996, 36:231-244. 10.1016/0168-8510(96)00815-9, 10158268.
29. Brouwer WB, Koopmanschap MA. The friction-cost method:replacement for nothing and leisure for free?. Pharmacoeconomics 2005, 23:105-111. 10.2165/00019053-200523020-00002, 15748085.
30. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189. 10.1016/0167-6296(94)00044-5, 10154656.
31. Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011, 63:3702-3711. 10.1002/art.30634, 21953215.
32. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63:573-586. 10.1002/art.30129, 3115717, 21294106.
33. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis:a three-year study of 7,527 patients. Arthritis Rheum 2003, 48:2750-2762. 10.1002/art.11439, 14558079.
34. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study:a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519, 16385520.
35. Keystone E, Heijde D, Mason D, Landewe R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis:findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329. 10.1002/art.23964, 18975346.
36. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial. Lancet 2004, 363:675-681. 10.1016/S0140-6736(04)15640-7, 15001324.
37. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915. 10.1056/NEJMoa035075, 14614165.
38. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis:Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602. 10.1056/NEJM200011303432202, 11096166.
39. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study):a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5, 18358926.
40. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement:a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030. 10.1002/art.20982, 15818697.
41. van der Heijde D, Kalden J, Scott D, Smolen J, Strand V. Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004, 63:737-739. 10.1136/ard.2003.010983, 1755041, 15140783.
42. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?. J Rheumatol 2010, 37:285-290. 10.3899/jrheum.090898, 20080905.
43. Chaparro Del Moral R, Rillo OL, Casalla L, Moron CB, Citera G, Cocco JA, Correa Mde L, Buschiazzo E, Tamborenea N, Mysler E, Tate G, Banos A, Herscovich N. Work productivity in rheumatoid arthritis:relationship with clinical and radiological features. Arthritis 2012, 2012:137635. [published online], 3535832, 23320166.
44. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413. 10.1136/ard.2011.149765, 21292833.